Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERPENTINE
2023-509619-10-00Phase 2Authorised
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Oct 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab and tremelimumab in colorectal cancer (CRC), endometrial cancer (EC) and microsatellite unstable colorectal cancer (2 cohorts), sponsored by Vall d'Hebron Institute of Oncology. Primary endpoint: Objective response rate (ORR). Planned start Oct 2024; status: authorised.
02
Drugs
durvalumabtremelimumab
03
Conditions
colorectal cancer (CRC)endometrial cancer (EC)microsatellite unstable colorectal cancer
Beyond the preview
Go deeper on 2023-509619-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509619-10-00.